Compare · OCGN vs RGNX
OCGN vs RGNX
Side-by-side comparison of Ocugen Inc. (OCGN) and REGENXBIO Inc. (RGNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OCGN and RGNX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RGNX is the larger of the two at $473.4M, about 1.8x OCGN ($262.3M).
- RGNX has been more active in the news (9 items in the past 4 weeks vs 7 for OCGN).
- RGNX has more recent analyst coverage (24 ratings vs 9 for OCGN).
- Company
- Ocugen Inc.
- REGENXBIO Inc.
- Price
- -
- -
- Market cap
- $262.3M
- $473.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2015
- News (4w)
- 7
- 9
- Recent ratings
- 9
- 24
Ocugen Inc.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Latest OCGN
- Ocugen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
- SEC Form DEFA14A filed by Ocugen Inc.
- SEC Form DEFA14A filed by Ocugen Inc.
- SEC Form 10-Q filed by Ocugen Inc.
- Ocugen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ocugen Provides Business Update with Third Quarter 2026 Financial Results
- Ocugen to Participate in Upcoming November Investor and Industry Conferences
- Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
- SEC Form 8-K filed by Ocugen Inc.
Latest RGNX
- SEC Form SCHEDULE 13G filed by REGENXBIO Inc.
- SEC Form 10-Q filed by REGENXBIO Inc.
- REGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
- Chief Technology Officer Malzahn Craig was granted 27,777 shares, increasing direct ownership by 34% to 109,737 units (SEC Form 4)
- Chief Strategy & Legal Officer Christmas Patrick J. was granted 34,722 shares, increasing direct ownership by 17% to 240,690 units (SEC Form 4)
- Chief Medical Officer Pakola Steve was granted 34,722 shares, increasing direct ownership by 17% to 240,263 units (SEC Form 4)
- Chief Financial Officer Chan Mitchell was granted 24,305 shares, increasing direct ownership by 20% to 147,120 units (SEC Form 4)
- REGENXBIO to Participate in Stifel 2026 Healthcare Conference
- REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights